Grant: Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus
| Project Title |
Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus
|
|---|---|
| Principal Investigator | Ho, James Chung Man (Principal investigator) |
| Co-Investigator(s) |
Ip, Mary Sau Man
(Co-Investigator)
Lam, Chi Leung David (Co-Investigator) Dr Lam Chung Mei Jamie (Co-Investigator) Dr Wong King Yan Matthew (Co-Investigator) |
| Funding Year |
2010/2011
|
| Amount |
51616
|
| Panel | Medicine |
| Start Date |
07-04-2010
|
| Expected Completion |
06-04-2012
|
| Status |
On-going
|
| Keywords | non-small cell lung cancer, anaplastic lymphoma kinase |
| Discipline | Cancer, Respiration |
| Grant Type/Funding Scheme | Pharmaceutical Industry - General Award |
| Duration |
24
|
[Coming Soon]